At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
VESANOID +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
In Brief
A Phase 2 clinical trial evaluating VESANOID and Ipilimumab for Melanoma. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of combined treatment with Ipilimumab and all-trans retinoic acid (ATRA) in melanoma patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartDec 2015
Primary CompletionAug 2018
Study CompletionJan 2023
TodayJul 2026
First PostedMar 31, 2015
Enrollment StartDec 17, 2015
Primary CompletionAug 1, 2018
Study CompletionJan 18, 2023
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.3 years ago
Interventions
VESANOIDdrug
All-trans retinoic acid (ATRA) is a vitamin A derivative that binds the retinoic acid receptor on MDSCs and differentiates immature monocytes into more mature dendritic cells (12). VESANOID is a standard treatment for patients with acute promyelocytic leukemia (APL).
Ipilimumabdrug
Ipilimumab is current standard of care treatment for melanoma.